Research & Development
Our cutting-edge R&D strategy is our blueprint and key driver for all our efforts. We harness interdisplinary technology scouting and out-of-the box thinking to innovate and bring the best technology solutions for our customers. With a committed and motivated team of leaders, our excellent team of scientists together with the feedback from the Scientific Advisory Board, we set high standards in our R & D .
Apotheca Biosciences has developed a novel combinatorial library of phyto and endocannabinoids for treating various diseases.
The endocannabinoid system (ECS) is composed of two G protein-coupled receptors (GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid ligands of such receptors, anandamide, and 2-arachidonoyl-glycerol(2-AG). The ECS is a pleiotropic signaling system involved in all aspects of mammalian physiology and pathology, and for this reason, it represents a potential target for the design and development of new therapeutic drugs. Over the past decades, the endocannabinoid system has been widely studied, owing to its broad range of physiological effects. ECS system encompasses a wide range of lipid mediators, proteins, and receptors, which together can be considered as the ‘endocannabinoidome’
Apotheca Biosciences has created an extensive library of various phyto-endo cannabinoid combinations in effective dose concentrations to modulate specific signaling to treat different human diseases.
Lead drug candidate to treat early stages of Alzheimer’s disease
Alzheimer’s disease (AD) represents a complex class of debilitating brain diseases that mostly affects people aged 65 and older. AD is characterized by progressive loss of neurons in the hippocampus and cortex, which results in the shrinkage of the brain. Basically, the brain cells required to process, store and retrieve information are killed, which is characteristic of a neurodegenerative process.
AD is a progressive neurodegenerative disorder, which killed half a million people in 2010. It is the sixth leading cause of death in US. It is estimated that by 2050, the number of people with AD may nearly triple, from 5 million to as many as 16 million, barring the development of medical breakthroughs to prevent, slow or stop the disease. Existing medications, which mostly treat symptoms, have combined sales of about $3 billion today. Any drug, which cures or manage to slow the progression of AD will be about $5-6billion dollar market.
Apotheca Biosciences has identified a combination of two patent-pending drug actives which simultaneously targets both amyloid plaques and tau phosphorylation, the two major causative agents of AD.
Opioid Crisis: A National Public Health Emergency
President Trump on October 26, 2017, directed the Department of Health and Human Services to declare the opioid crisis a public health emergency, taking long-anticipated action to address a rapidly escalating epidemic of drug use. The United States is in the middle of an unprecedented opioid epidemic; Since 2000, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic. Data is showing that on an average day in the US about 140 people die from an opioid-related overdose, most of the ones died belongs to the younger population.
Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. Apotheca Biosciences’ preliminary studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. Apotheca Biosciences has been developing various cannabinoid formulations for relieving various pains and opioid withdrawal symptoms. There is strong evidence that cannabinoid compounds can relieve depression caused by drug addiction.
Apotheca Biosciences’ initiative on Opioid Addiction
A cannabidiol based cannabinoid formulation recently developed by Apotheca Biosciences that represents a select combination of phytocannabinoids assembled to specifically target opioid. Apotheca Biosciences has identified a combination of patent-pending drug actives which targets and blocks rewarding neuronal effects.
Lead drug candidate to treat Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) also known as “asthma of the esophagus” is a chronic immune-mediated disorder of the esophagus affecting both children and adults. EoE is a major cause of chronic esophagitis, second to gastro-esophageal reflux. Patients present with abdominal pain, vomiting, and dysphagia, difficulty swallowing and food impaction. It can be refractory to standard treatment with strict dietary food allergen avoidance, off-label use of swallowed topical steroids and proton pump inhibitors.
- EoE is an orphan disease.
- Overall prevalence is 57 per 100,000 United States children and adults up to age 64.
- EoE profoundly impacts the quality of life in EoE patients.
- This life-long disease of adults and children has a United States prevalence of approximately 181,000.
- An economic burden of $1.4B in annual direct health care.
- There are no FDA-approved EoE treatments.
Apotheca Biosciences has applied for two world-wide patent rights for the platform technologies and for specific novel drug formulations. We are actively procuring a portfolio of patents, trademarks, and trade secrets to reinforce and protect our technologies. We are conducting discovery research both in-house and with joint development agreements using our platform technology. Further, we are currently exploring technology licensing from major academic institutions to complement our tech-portfolio.